Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.

van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J, van Nuenen AC, Beuers U, Hadi S, Harbers M, van der Veer E, Liu K, Grundy J, Patick AK, Pavlicek A, Blem J, Huang M, Grint P, Neben S, Gibson NW, Kootstra NA, Reesink HW.

Lancet. 2017 Feb 18;389(10070):709-717. doi: 10.1016/S0140-6736(16)31715-9. Epub 2017 Jan 11.

PMID:
28087069
2.

In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.

Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der Veer E, Raney AK, Hodges MR, Patick AK.

Antimicrob Agents Chemother. 2015 Jan;59(1):599-608. doi: 10.1128/AAC.04220-14. Epub 2014 Nov 10.

3.

Treatment of HCV infection by targeting microRNA.

Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR.

N Engl J Med. 2013 May 2;368(18):1685-94. doi: 10.1056/NEJMoa1209026. Epub 2013 Mar 27.

4.

Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.

Binder J, Tetangco S, Weinshank M, Maegley K, Lingardo L, Diehl W, Love R, Patick AK, Smith GJ 3rd.

Antiviral Res. 2011 Aug;91(2):102-11. doi: 10.1016/j.antiviral.2011.05.007. Epub 2011 May 19.

PMID:
21620899
5.

HIV capsid is a tractable target for small molecule therapeutic intervention.

Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, Cao J, Ciaramella G, Isaacson J, Jackson L, Hunt R, Kjerrstrom A, Nieman JA, Patick AK, Perros M, Scott AD, Whitby K, Wu H, Butler SL.

PLoS Pathog. 2010 Dec 9;6(12):e1001220. doi: 10.1371/journal.ppat.1001220.

6.

Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.

Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, Faix DJ, Blair PJ, de Jong MD, Prichard MN, Went GT.

PLoS One. 2010 Feb 22;5(2):e9332. doi: 10.1371/journal.pone.0009332.

7.

New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.

Blair WS, Cao J, Fok-Seang J, Griffin P, Isaacson J, Jackson RL, Murray E, Patick AK, Peng Q, Perros M, Pickford C, Wu H, Butler SL.

Antimicrob Agents Chemother. 2009 Dec;53(12):5080-7. doi: 10.1128/AAC.00759-09. Epub 2009 Oct 5.

8.

Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.

Shi ST, Herlihy KJ, Graham JP, Nonomiya J, Rahavendran SV, Skor H, Irvine R, Binford S, Tatlock J, Li H, Gonzalez J, Linton A, Patick AK, Lewis C.

Antimicrob Agents Chemother. 2009 Jun;53(6):2544-52. doi: 10.1128/AAC.01599-08. Epub 2009 Mar 23.

9.

Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.

Herlihy KJ, Graham JP, Kumpf R, Patick AK, Duggal R, Shi ST.

Antimicrob Agents Chemother. 2008 Oct;52(10):3523-31. doi: 10.1128/AAC.00533-08. Epub 2008 Aug 11.

10.

Potential use of antiviral agents in polio eradication.

De Palma AM, PĆ¼rstinger G, Wimmer E, Patick AK, Andries K, Rombaut B, De Clercq E, Neyts J.

Emerg Infect Dis. 2008 Apr;14(4):545-51. doi: 10.3201/eid1404.070439.

11.

In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.

Shi ST, Herlihy KJ, Graham JP, Fuhrman SA, Doan C, Parge H, Hickey M, Gao J, Yu X, Chau F, Gonzalez J, Li H, Lewis C, Patick AK, Duggal R.

Antimicrob Agents Chemother. 2008 Feb;52(2):675-83. Epub 2007 Dec 10.

12.

In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.

Binford SL, Weady PT, Maldonado F, Brothers MA, Matthews DA, Patick AK.

Antimicrob Agents Chemother. 2007 Dec;51(12):4366-73. Epub 2007 Oct 1.

13.

Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing.

Blair WS, Cao J, Jackson L, Jimenez J, Peng Q, Wu H, Isaacson J, Butler SL, Chu A, Graham J, Malfait AM, Tortorella M, Patick AK.

Antimicrob Agents Chemother. 2007 Oct;51(10):3554-61. Epub 2007 Jul 23.

14.

Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening.

Hao W, Herlihy KJ, Zhang NJ, Fuhrman SA, Doan C, Patick AK, Duggal R.

Antimicrob Agents Chemother. 2007 Jan;51(1):95-102. Epub 2006 Oct 23.

15.

Rhinovirus chemotherapy.

Patick AK.

Antiviral Res. 2006 Sep;71(2-3):391-6. Epub 2006 Apr 18. Review.

PMID:
16675037
16.

In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.

Sato A, Hammond J, Alexander TN, Graham JP, Binford S, Sugita K, Sugimoto H, Fujiwara T, Patick AK.

Antiviral Res. 2006 Jun;70(2):66-74. Epub 2006 Jan 25.

PMID:
16472877
17.
18.

In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease.

Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ 3rd, Zalman LS, Burns-Naas LA, Tran JQ.

Antimicrob Agents Chemother. 2005 Jun;49(6):2267-75.

19.

A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors.

Blair WS, Isaacson J, Li X, Cao J, Peng Q, Kong GF, Patick AK.

Antiviral Res. 2005 Feb;65(2):107-16.

PMID:
15708637
20.

Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.

Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW 3rd, Matthews DA, Patick AK.

Antimicrob Agents Chemother. 2005 Feb;49(2):619-26.

21.

An optical thin film assay incorporating rhinovirus protease inhibitors as detector reagents.

Ettinger A, Ostroff R, Rhihanek M, Dragovich PS, Zalman LS, Patick AK, Prins TJ, Fuhrman SA, Brown EL, Worland ST, Polisky B.

Antiviral Res. 2004 Mar;61(3):153-9.

PMID:
15168795
22.

Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers.

Hayden FG, Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, Hsyu P, Patick AK, Smith GJ 3rd, Zalman LS.

Antimicrob Agents Chemother. 2003 Dec;47(12):3907-16.

23.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW 3rd, Ferre RA.

J Med Chem. 2003 Oct 9;46(21):4572-85.

PMID:
14521419
24.

Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease.

Johnson TO, Hua Y, Luu HT, Brown EL, Chan F, Chu SS, Dragovich PS, Eastman BW, Ferre RA, Fuhrman SA, Hendrickson TF, Maldonado FC, Matthews DA, Meador JW 3rd, Patick AK, Reich SH, Skalitzky DJ, Worland ST, Yang M, Zalman LS.

J Med Chem. 2002 May 9;45(10):2016-23.

PMID:
11985469
25.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Tuntland T, Lee CA, Patick AK, Matthews DA, Hendrickson TF, Kosa MB, Liu B, Batugo MR, Gleeson JP, Sakata SK, Chen L, Guzman MC, Meador JW 3rd, Ferre RA, Worland ST.

J Med Chem. 2002 Apr 11;45(8):1607-23.

PMID:
11931615
26.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Johnson TO, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Hou X, Meador JW, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 2002 Mar 11;12(5):733-8.

PMID:
11858991
27.

Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.

Webber SE, Marakovits JT, Dragovich PS, Prins TJ, Zhou R, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Srinivasan B, Moran T, Ford CE, Brothers MA, Harr JE, Meador JW 3rd, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 2001 Oct 22;11(20):2683-6.

PMID:
11591501
28.

Rapid multiserotype detection of human rhinoviruses on optically coated silicon surfaces.

Ostroff R, Ettinger A, La H, Rihanek M, Zalman L, Meador J 3rd, Patick AK, Worland S, Polisky B.

J Clin Virol. 2001 May;21(2):105-17.

PMID:
11378491
29.

Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.

Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Shetty B, Webber S.

Antimicrob Agents Chemother. 2001 Apr;45(4):1086-93. Erratum in: Antimicrob Agents Chemother 2001 Aug;45(8):2405.

30.
31.

Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation.

Reich SH, Johnson T, Wallace MB, Kephart SE, Fuhrman SA, Worland ST, Matthews DA, Hendrickson TF, Chan F, Meador J 3rd, Ferre RA, Brown EL, DeLisle DM, Patick AK, Binford SL, Ford CE.

J Med Chem. 2000 May 4;43(9):1670-83.

PMID:
10794684
32.

Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor.

Zalman LS, Brothers MA, Dragovich PS, Zhou R, Prins TJ, Worland ST, Patick AK.

Antimicrob Agents Chemother. 2000 May;44(5):1236-41.

33.

Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors.

Dragovich PS, Zhou R, Webber SE, Prins TJ, Kwok AK, Okano K, Fuhrman SA, Zalman LS, Maldonado FC, Brown EL, Meador JW 3rd, Patick AK, Ford CE, Brothers MA, Binford SL, Matthews DA, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 2000 Jan 3;10(1):45-8.

PMID:
10636240
34.

In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.

Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST.

Antimicrob Agents Chemother. 1999 Oct;43(10):2444-50.

35.

Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11000-7.

36.

Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids.

Dragovich PS, Webber SE, Prins TJ, Zhou R, Marakovits JT, Tikhe JG, Fuhrman SA, Patick AK, Matthews DA, Ford CE, Brown EL, Binford SL, Meador JW 3rd, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 1999 Aug 2;9(15):2189-94.

PMID:
10465543
38.

Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides.

Dragovich PS, Zhou R, Skalitzky DJ, Fuhrman SA, Patick AK, Ford CE, Meador JW 3rd, Worland ST.

Bioorg Med Chem. 1999 Apr;7(4):589-98.

PMID:
10353638
39.

Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.

Tebas P, Patick AK, Kane EM, Klebert MK, Simpson JH, Erice A, Powderly WG, Henry K.

AIDS. 1999 Feb 4;13(2):F23-8.

PMID:
10202820
40.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.

Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador JW 3rd, Ferre RA, Harr JE, Kosa MB, Worland ST.

J Med Chem. 1999 Apr 8;42(7):1213-24.

PMID:
10197965
41.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Fuhrman SA, Patick AK, Matthews DA, Ford CE, Meador JW 3rd, Ferre RA, Worland ST.

J Med Chem. 1999 Apr 8;42(7):1203-12.

PMID:
10197964
42.

Protease inhibitors as antiviral agents.

Patick AK, Potts KE.

Clin Microbiol Rev. 1998 Oct;11(4):614-27. Review.

43.

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

Patick AK, Duran M, Cao Y, Shugarts D, Keller MR, Mazabel E, Knowles M, Chapman S, Kuritzkes DR, Markowitz M.

Antimicrob Agents Chemother. 1998 Oct;42(10):2637-44.

44.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.

Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Reich SH, Marakovits JT, Prins TJ, Zhou R, Tikhe J, Littlefield ES, Bleckman TM, Wallace MB, Little TL, Ford CE, Meador JW 3rd, Ferre RA, Brown EL, Binford SL, DeLisle DM, Worland ST.

J Med Chem. 1998 Jul 16;41(15):2819-34.

PMID:
9667971
45.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.

Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Reich SH, Prins TJ, Marakovits JT, Littlefield ES, Zhou R, Tikhe J, Ford CE, Wallace MB, Meador JW 3rd, Ferre RA, Brown EL, Binford SL, Harr JE, DeLisle DM, Worland ST.

J Med Chem. 1998 Jul 16;41(15):2806-18.

PMID:
9667970
46.

Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.

Webber SE, Okano K, Little TL, Reich SH, Xin Y, Fuhrman SA, Matthews DA, Love RA, Hendrickson TF, Patick AK, Meador JW 3rd, Ferre RA, Brown EL, Ford CE, Binford SL, Worland ST.

J Med Chem. 1998 Jul 16;41(15):2786-805.

PMID:
9667969
47.
48.

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

Kaldor SW, Kalish VJ, Davies JF 2nd, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH.

J Med Chem. 1997 Nov 21;40(24):3979-85.

PMID:
9397180
50.

Comparison of human cytomegalovirus (HCMV) protease sequences among laboratory strains and seven clinical isolates.

Huffaker TK, Binford S, Patick AK, Pinko C, Kan CC, Zalman LS.

Antiviral Res. 1997 Feb;33(3):215-8.

PMID:
9037377

Supplemental Content

Loading ...
Support Center